The emerging role of glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RAs) as a therapeutic option for obese women with PCOS has been reported in adult age, and the benefits in adolescents could be considered [40,41]. Here, GCG is linked to polycystic ovary syndrome.